Assessment of tumor response
SD, Tumor
DISEASE, TUMOR
Baseline radiographic imaging (e.g., computed tomography (CT) scan or magnetic resonance imaging (MRI)) was performed within four weeks of the start of treatment. Tumor measurements were performed on patients at baseline and at the end of every two cycles (three cycles after 24 weeks). Measurable target lesions were evaluated for response using RECIST v1.1. For purposes of this report, prolonged stable disease (SD) was defined as lasting ≥ 16 weeks.